Low Dose Dehydroepiandrosterone Affects Behavior in Hypopituitary Androgen-Deficient Women: A Placebo-Controlled Trial
Gudmundur Johannsson,
Pia Burman,
Lena Wirén,
Britt Edén Engström,
Anna G. Nilsson,
Malin Ottosson,
Björn Jonsson,
Bengt-Åke Bengtsson and
F. Anders Karlsson
Research Center for Endocrinology and Metabolism, Sahlgrenska University Hospital (G.J., L.W., M.O., B.-Å.B.), SE-413 45 Goteborg, Sweden; Department of Medical Sciences, Uppsala University Hospital (P.B., B.E.E., A.G.N., F.A.K.), SE-751 85 Uppsala, Sweden; and Department of Women’s and Children’s Health, Karolinska Institute (B.J.), SE-171 77 Stockholm, Sweden
Address all correspondence and requests for reprints to: Gudmundur Johannsson, M.D., Ph.D., Research Center for Endocrinology and Metabolism, Sahlgrenska University Hospital, SE-413 45 Goteborg, Sweden. E-mail: . gudmundur.johannsson{at}medic.gu.se
Abstract
Thirty-eight women, aged 25–65 yr, with androgen deficiencydue to hypopituitarism were treated with oral dehydroepiandrosterone(DHEA; 30 mg/d if <45 yr of age and 20 mg if 45 yr of age)for 6 months in a randomized, placebo-controlled, double blindstudy, followed by a 6-month open treatment period. The administrationof DHEA raised the serum levels of DHEAS to normal age-relatedreference ranges and increased androstenedione and T to subnormallevels. Androgen effects on skin and/or pubic and/or axillaryhair were observed in 84% (32 of 38) of the women after allreceived 6 months of DHEA treatment. No such effects were observedafter the placebo treatment. These effects after 6 months werecorrelated with the serum levels of DHEAS (r = 0.37; P = 0.03),androstenedione (r = 0.42; P = 0.01), and T (r = 0.37; P = 0.03).The percentages of partners who reported improved alertness,stamina, and initiative by their spouses were 70%, 64%, and55%, respectively, in the DHEA group and 11%, 6%, and 11%, respectively,in the placebo group (P < 0.05). According to the partners,sexual relations tended to improve compared with placebo (P= 0.06). After 6 months of treatment, increased sexual interestor activity was reported by 50% of the women taking 30 mg DHEA,by none taking 20 mg DHEA, and by two women taking placebo (P= NS). Compared with levels after placebo administration, highdensity lipoprotein cholesterol and apolipoprotein A-1 levelsdecreased after DHEA. Serum concentrations of IGF-I, serum markersof bone metabolism, and bone density did not change.
In conclusion, oral administration of a low dose of DHEA toadult hypopituitary women induced androgen effects on skin andaxillary and pubic hair as well as changes in behavior, withonly minor effects on metabolism.
This article has been cited by other articles:
A. A. Alkatib, M. Cosma, M. B. Elamin, D. Erickson, B. A. Swiglo, P. J. Erwin, and V. M. Montori A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials of DHEA Treatment Effects on Quality of Life in Women with Adrenal Insufficiency
J. Clin. Endocrinol. Metab.,
October 1, 2009;
94(10):
3676 - 3681.
[Abstract][Full Text][PDF]
S. P. L. Rice, N. Agarwal, H. Bolusani, R. Newcombe, M. F. Scanlon, M. Ludgate, and D. A. Rees Effects of Dehydroepiandrosterone Replacement on Vascular Function in Primary and Secondary Adrenal Insufficiency: A Randomized Crossover Trial
J. Clin. Endocrinol. Metab.,
June 1, 2009;
94(6):
1966 - 1972.
[Abstract][Full Text][PDF]
W. Arlt The Approach to the Adult with Newly Diagnosed Adrenal Insufficiency
J. Clin. Endocrinol. Metab.,
April 1, 2009;
94(4):
1059 - 1067.
[Abstract][Full Text][PDF]
G. Binder, S. Weber, M. Ehrismann, N. Zaiser, C. Meisner, M. B. Ranke, L. Maier, S. A. Wudy, M. F. Hartmann, U. Heinrich, et al. Effects of Dehydroepiandrosterone Therapy on Pubic Hair Growth and Psychological Well-Being in Adolescent Girls and Young Women with Central Adrenal Insufficiency: A Double-Blind, Randomized, Placebo-Controlled Phase III Trial
J. Clin. Endocrinol. Metab.,
April 1, 2009;
94(4):
1182 - 1190.
[Abstract][Full Text][PDF]
E. M. Gurnell, P. J. Hunt, S. E. Curran, C. L. Conway, E. M. Pullenayegum, F. A. Huppert, J. E. Compston, J. Herbert, and V. K. K. Chatterjee Long-Term DHEA Replacement in Primary Adrenal Insufficiency: A Randomized, Controlled Trial
J. Clin. Endocrinol. Metab.,
February 1, 2008;
93(2):
400 - 409.
[Abstract][Full Text][PDF]
A Hartkamp, R Geenen, G L R Godaert, H Bootsma, A A Kruize, J W J Bijlsma, and R H W M Derksen Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trial
Ann Rheum Dis,
January 1, 2008;
67(1):
91 - 97.
[Abstract][Full Text][PDF]
J. Gibney, M.-L. Healy, and P. H. Sonksen The Growth Hormone/Insulin-Like Growth Factor-I Axis in Exercise and Sport
Endocr. Rev.,
October 1, 2007;
28(6):
603 - 624.
[Abstract][Full Text][PDF]
S. Hahner, M. Loeffler, M. Fassnacht, D. Weismann, A.-C. Koschker, M. Quinkler, O. Decker, W. Arlt, and B. Allolio Impaired Subjective Health Status in 256 Patients with Adrenal Insufficiency on Standard Therapy Based on Cross-Sectional Analysis
J. Clin. Endocrinol. Metab.,
October 1, 2007;
92(10):
3912 - 3922.
[Abstract][Full Text][PDF]
K. Lovas and E. S Husebye Continuous subcutaneous hydrocortisone infusion in Addison's disease
Eur. J. Endocrinol.,
July 1, 2007;
157(1):
109 - 112.
[Abstract][Full Text][PDF]
M. Panjari and S. R. Davis DHEA therapy for women: effect on sexual function and wellbeing
Hum. Reprod. Update,
May 1, 2007;
13(3):
239 - 248.
[Abstract][Full Text][PDF]
A. M. Brooke, L. A. Kalingag, F. Miraki-Moud, C. Camacho-Hubner, K. T. Maher, D. M. Walker, J. P. Hinson, and J. P. Monson Dehydroepiandrosterone Improves Psychological Well-Being in Male and Female Hypopituitary Patients on Maintenance Growth Hormone Replacement
J. Clin. Endocrinol. Metab.,
October 1, 2006;
91(10):
3773 - 3779.
[Abstract][Full Text][PDF]
M. E. Wierman, R. Basson, S. R. Davis, S. Khosla, K. K. Miller, W. Rosner, and N. Santoro Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline
J. Clin. Endocrinol. Metab.,
October 1, 2006;
91(10):
3697 - 3710.
[Abstract][Full Text][PDF]
K. K. Miller, B. M. K. Biller, C. Beauregard, J. G. Lipman, J. Jones, D. Schoenfeld, J. C. Sherman, B. Swearingen, J. Loeffler, and A. Klibanski Effects of Testosterone Replacement in Androgen-Deficient Women with Hypopituitarism: A Randomized, Double-Blind, Placebo-Controlled Study
J. Clin. Endocrinol. Metab.,
May 1, 2006;
91(5):
1683 - 1690.
[Abstract][Full Text][PDF]
W. Arlt Androgen therapy in women
Eur. J. Endocrinol.,
January 1, 2006;
154(1):
1 - 11.
[Abstract][Full Text][PDF]
S. W. van Thiel, J. A. Romijn, A. M. Pereira, N. R. Biermasz, F. Roelfsema, A. van Hemert, B. Ballieux, and J. W. A. Smit Effects of Dehydroepiandrostenedione, Superimposed on Growth Hormone Substitution, on Quality of Life and Insulin-Like Growth Factor I in Patients with Secondary Adrenal Insufficiency: A Randomized, Placebo-Controlled, Cross-Over Trial
J. Clin. Endocrinol. Metab.,
June 1, 2005;
90(6):
3295 - 3303.
[Abstract][Full Text][PDF]
J. J. Christiansen, S. Fisker, C. H. Gravholt, P. Bennett, B. Svenstrup, M. Andersen, U. Feldt-Rasmussen, J. S. Christiansen, and J. O. L. Jorgensen Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I
Eur. J. Endocrinol.,
May 1, 2005;
152(5):
719 - 726.
[Abstract][Full Text][PDF]
S. A. Boone and K. M. Shields Dietary supplements for female sexual dysfunction
Am. J. Health Syst. Pharm.,
March 15, 2005;
62(6):
574 - 580.
[Full Text][PDF]
P. J. Schmidt, R. C. Daly, M. Bloch, M. J. Smith, M. A. Danaceau, L. Simpson St. Clair, J. H. Murphy, N. Haq, and D. R. Rubinow Dehydroepiandrosterone Monotherapy in Midlife-Onset Major and Minor Depression
Arch Gen Psychiatry,
February 1, 2005;
62(2):
154 - 162.
[Abstract][Full Text][PDF]
J. J. Christiansen, C. H. Gravholt, S. Fisker, N. Moller, M. Andersen, B. Svenstrup, P. Bennett, P. Ivarsen, J. S. Christiansen, and J. O. L. Jorgensen Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism
Eur. J. Endocrinol.,
January 1, 2005;
152(1):
77 - 85.
[Abstract][Full Text][PDF]
L.M. Rivera-Woll, M. Papalia, S.R. Davis, and H.G. Burger Androgen insufficiency in women: diagnostic and therapeutic implications
Hum. Reprod. Update,
September 1, 2004;
10(5):
421 - 432.
[Abstract][Full Text][PDF]
K. K. Dhatariya and K. S. Nair Dehydroepiandrosterone: Is There a Role for Replacement?
Mayo Clin. Proc.,
October 1, 2003;
78(10):
1257 - 1273.
[Abstract][PDF]
W. Arlt and B. Allolio DHEA Replacement in Adrenal Insufficiency
J. Clin. Endocrinol. Metab.,
August 1, 2003;
88(8):
4001 - 4001.
[Full Text][PDF]
K. Lovas, O. Kampe, and E. S. Husebye Authors' Response: DHEA Replacement in Adrenal Insufficiency
J. Clin. Endocrinol. Metab.,
August 1, 2003;
88(8):
4001 - 4002.
[Full Text]
J. Svensson, K. Stibrant Sunnerhagen, and G. Johannsson Five Years of Growth Hormone Replacement Therapy in Adults: Age- and Gender-Related Changes in Isometric and Isokinetic Muscle Strength
J. Clin. Endocrinol. Metab.,
May 1, 2003;
88(5):
2061 - 2069.
[Abstract][Full Text][PDF]
45 yr of age) for 6 months in a randomized, placebo-controlled, double blind study, followed by a 6-month open treatment period. The administration of DHEA raised the serum levels of DHEAS to normal age-related reference ranges and increased androstenedione and T to subnormal levels. Androgen effects on skin and/or pubic and/or axillary hair were observed in 84% (32 of 38) of the women after all received 6 months of DHEA treatment. No such effects were observed after the placebo treatment. These effects after 6 months were correlated with the serum levels of DHEAS (r = 0.37; P = 0.03), androstenedione (r = 0.42; P = 0.01), and T (r = 0.37; P = 0.03). The percentages of partners who reported improved alertness, stamina, and initiative by their spouses were 70%, 64%, and 55%, respectively, in the DHEA group and 11%, 6%, and 11%, respectively, in the placebo group (P < 0.05). According to the partners, sexual relations tended to improve compared with placebo (P = 0.06). After 6 months of treatment, increased sexual interest or activity was reported by 50% of the women taking 30 mg DHEA, by none taking 20 mg DHEA, and by two women taking placebo (P = NS). Compared with levels after placebo administration, high density lipoprotein cholesterol and apolipoprotein A-1 levels decreased after DHEA. Serum concentrations of IGF-I, serum markers of bone metabolism, and bone density did not change. 
